Correlation of changes in serum level of VEGF and peripapillary retinal thickness in patients with POEMS syndrome

2019 ◽  
Vol 104 (1) ◽  
pp. 33-38
Author(s):  
Hirotaka Yokouchi ◽  
Takayuki Baba ◽  
Sonoko Misawa ◽  
Toshiyuki Oshitari ◽  
Satoshi Kuwabara ◽  
...  
Keyword(s):  
Serum Level ◽  
Retinal Thickness ◽  
Case Series ◽  
Serum Levels ◽  
Poems Syndrome ◽  
Vascular Endothelial ◽  
Close Relationship ◽  
Treatment Naïve ◽  
Endothelial Growth Factor ◽  
Thalidomide Treatment

AimTo determine whether changes in the serum levels of vascular endothelial growth factor (VEGF) after thalidomide therapy will affect the peripapillary retinal thickness (pRT) associated with optic disc oedema (ODE) in patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes (POEMS) syndrome.MethodsThis was a retrospective, observational case series of 23 right eyes of 23 treatment-naïve patients with POEMS syndrome and ODE whose intracranial pressure was within the normal range. The pRT was determined by spectral-domain optical coherence tomography, and the serum level of VEGF was determined by ELISA at baseline and 6 months after the thalidomide therapy. We determined whether a change in the pRT from baseline was significantly correlated with the serum level of VEGF from that at 6 months after the thalidomide treatment.ResultsSix months after treatment, the mean serum level of VEGF was significantly reduced from 7153±4214 pg/mL to 1067±769 pg/mL (p<0.001), and the pRT was significantly decreased from 471.2±203 µm to 318.1±53.9 µm (p<0.001). The change in the pRT from baseline was significantly and linearly correlated with the change in the serum level of VEGF from that at 6 months after treatment (r=0.67, p=0.00039).ConclusionsThe close relationship between the pRT and the serum level of VEGF may offer clues on the pathogenesis of POEMS syndrome and potentially add a new candidate cause for the pathogenesis of ODE.

Elevated Serum Level of Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Correlates with Stage of Chronic Lymphocytic Leukemia and Resistance to Treatment

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 4172-4172
Author(s):  
Bulat Bakirov ◽  
Anastasiya Sgibneva ◽  
Akhat Bakirov
Keyword(s):  
Growth Factor ◽  
High Risk ◽  
Serum Level ◽  
Serum Levels ◽  
Lymphocytic Leukemia ◽  
Control Group ◽  
Vascular Endothelial ◽  
Fibroblast Growth ◽  
High Risk Disease ◽  
Endothelial Growth Factor

Abstract Background: B-cell chronic lymphocytic leukemia (B-CLL) is the most common leukemia in western world with an incidence of 3,36/100,000 in European males. It is characterized by a clonal growth of long lived, slowly proliferating mature B lymphoid cells in the bone marrow (BM), peripheral blood (PB), and lymphoid tissues. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) is a pleiotropic cytokine that plays a role in hematopoiesis and apoptosis. Angiogenesis may have a role in a pathophysiology of leukemias and antiangiogenesis therapy could have an anticancer effect. Aim: analyze the clinical significance of serum levels of angiogenic factors and how it’s correlate with clinical stage and survival in patients with B-CLL Methods: the enzyme-linked immunosorbent assays (ELISAs) for VEGF and bFGF were performed in 78 CLL patients and 29 healthy person as a control group. The patients was divided on low-risk disease (44 patients) and high-risk disease (34 patients). Results: VEGF and bFGF serum levels were significantly increased in patient with high-risk disease, the median serum VEGF level was 185.66 pg/ml, compared with 72.67 pg/ml in patient with a low-risk and in control, it was 48.62 pg/ml. The difference in the VEGF levels was significant for the comparison between low- and high-risk disease (p&lt;0.001). VEGF levels correlate with high white blood cell/lymphocyte counts, short period of time to begin treatment, disease progression, lymphocyte doubling time and worse answer to chemotherapy. No significant increase was found in bFGF serum level between low- and high-risk disease (34.06 pg/ml and 35.84 pg/ml, respectevely), but between patient and control group it was differences in serum level of bFGF (34.85 pg/ml and 7.77 pg/ml, respectively) (p&lt;0.001). Conclusion: as we found, serum levels of bFGF and VEGF were significantly higher in the patients with B-CLL than in controls. High serum level of VEGF and bFGF associated with poor prognosis and worse answer on treatment. In summary, our data suggest that angiogenic factors play a significant role in the leukemic process and may suggest novel therapeutic approaches in B-CLL.

scholarly journals Circulating MiRNA-195-5p and -451a in Transient and Acute Ischemic Stroke Patients in an Emergency Department

2019 ◽  
Vol 8 (2) ◽  
pp. 130 ◽  
Author(s):  
Mauro Giordano ◽  
Tiziana Ciarambino ◽  
Michele D’Amico ◽  
Maria Trotta ◽  
Alessandra Di Sette ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Serum Level ◽  
Acute Ischemic Stroke ◽  
Hypoxia Inducible Factor ◽  
Serum Levels ◽  
Vascular Endothelial ◽  
Circulating Mirna ◽  
Elevated Expression ◽  
Ischemic Attack ◽  
Endothelial Growth Factor

We have evaluated circulating miRNAs (-195-5p and -451a) in subjects with acute ischemic stroke (AIS) and in patients with transient ischemic attack (TIA). In this study, 18 subjects with AIS and 18 patients with TIA were enrolled and examined at admission (T0) and at 24 h and 48 h after admission, and compared to 20 controls (C). At T0, circulating miRNA-195-5p and -451a were significantly upregulated in both AIS and TIA patients, compared to C. We also observed a progressive reduction of circulating miRNA levels at 24 h and 48 h in both AIS and TIA patients. Hypoxia inducible factor 1alpha (HIF-1α) serum level was significantly increased at T0, in both AIS and TIA patients, in comparison to C (both p < 0.01 vs. C) and it decreased in both AIS and TIA patients at 24 h and at 48 h, in comparison to T0 (both p < 0.01 vs. T0). Vascular endothelial growth factor (VEGF) serum level was significantly decreased at T0, in both AIS and TIA patients, if compared to C (both p < 0.01 vs. C) and increased, in both AIS and TIA patients, at 24 h and 48 h, if compared to T0 (both p < 0.01 vs. T0). The elevated expression of miRNA-195-5p and miRNA-451a significantly decreased over time at 24 h and 48 h, and it is associated with decreased HIF-α levels and increased VEGF serum levels. These data may suggest a role for this miRNAs as biomarker in the pathogenesis and prognosis of AIS patients and for the first time also in TIA patients.

scholarly journals The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome

Blood ◽  
2011 ◽  
Vol 118 (17) ◽  
pp. 4663-4665 ◽  
Author(s):  
Anita D'Souza ◽  
Suzanne R. Hayman ◽  
Francis Buadi ◽  
Michelle Mauermann ◽  
Martha Q. Lacy ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Serum Levels ◽  
Poems Syndrome ◽  
Vascular Endothelial ◽  
Plasma Cell Dyscrasias ◽  
Disease Entities ◽  
Endothelial Growth Factor ◽  
Better Than

Abstract The POEMS syndrome is associated with elevated vascular endothelial growth factor (VEGF) levels. Several studies have compared serum VEGF levels between POEMS patients and other disease entities showing higher serum VEGF in POEMS syndrome; however, it is unknown whether serum levels are reliable and reproducible given variable platelet release of VEGF. We therefore compared plasma levels of VEGF in 29 patients with POEMS syndrome with those of other disorders (n = 76). We demonstrated that plasma VEGF levels are useful in differentiating POEMS from other plasma cell dyscrasias, neuropathic processes, and multisystem illnesses. Plasma VEGF is also useful in monitoring disease activity after treatment and correlates with clinical improvements better than hematologic response.

Serum Values of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Parameters in Patients with Multiple Myeloma

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 4993-4993
Author(s):  
Toni Valkovic ◽  
Emina Babarovic ◽  
Merica Aralica ◽  
Sanja Stifter ◽  
Antica Duletic-Nacinovic ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Vascular Endothelial Growth Factor ◽  
Serum Level ◽  
Serum Levels ◽  
Control Group ◽  
Clinical Parameters ◽  
Vascular Endothelial ◽  
Tumor Mass ◽  
Endothelial Growth Factor

Abstract Abstract 4993 Background: the role of osteopontin (OPN), glyco-phosphoprotein produced by variety of tissues, has been widely investigated in the progression of many solid tumors, but on the other side, there are not many studies performed in multiple myeloma (MM). The role of Vascular Endothelial Growth Factor (VEGF) in tumor angiogenesis, as well as in MM, has been extensively analysed, but the significance of its serum level is still not well recognize. The aim of the present study was to determine the serum levels of both above mentioned cytokines and compare their values with clinical parameters of myeloma patients. Methods: serum level of OPN and VEGF was determinated by ELISA in 44 newly-diagnosed, reviously untreated myeloma patients (21 men, 22 women; median age of 69, range 44 – 86) and 24 age-matched healthy persons who consisted control group. The obtained values were correlated with main clinical parameters such as anaemia (hemoglobine value 20 g/L below the lower limit of normal), renal dysfunction (serum creatinine level above the uper limit of normal) and bone disease (any of lytic lesions or severe osteopenia with compressive fractures on standard radiographs of the bones). The level of cytokines were also correlated with serum beta-2 microglobulin as a prognostic factor related to biological behaviour of MM, and Durie-Salmon Staging System as a measure of tumor mass. Results: serum value of OPN was significantly higher in myeloma patients (median 6. 5, range 0. 3 – 21. 7) in compare to control group (medain 2. 4, range 0. 2 – 8. 9) (p<0. 0001), while these difference could not be observed with VEGF (52. 5 versus 60. 5) (p=0. 6673). Serum level of beta2-microglobuline was positively associated with value of OPN (p=0. 0461) but not with VEGF (p=0. 79). Patients with lower Durie-Salmon Stage had significantly lower both- OPN and VEGF serum levels (p=0. 0456, p=0, 0371 respectively). Higher OPN serum value was found in MM patients with evident bone lesions (p=0. 0268), while this difference was not observed with VEGF (p= 0. 7962). There was no correlation between serum levels of OPN and anaemia (p=0. 2991) or increased serum creatinine (p=0. 1338). VEGF serum level, also, did not correlated with anemia (p=0. 4309) and renal dysfunction (p=0. 5119). Conclusion: our preliminary results support the serum level of OPN as a dual marker of tumor aggressiveness and bone destrucion. On the contrary, present study did not confirm similar clinical value of VEGF serum level which represent a critical angiogenic factor in tumor micro-eco system. However, in our investigation both cytokines positively correlated with tumor burden. Further analysis with more included patient sholud provide definitive information about possible role of OPN as a useful clinical biomarker for monitoring of bone disease and tumor mass, as well as prognostic factor during course of disease. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document